Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140

被引:114
作者
Tamamura, H
Omagari, A
Hiramatsu, K
Gotoh, K
Kanamoto, T
Xu, YN
Kodama, E
Matsuoka, M
Hattori, T
Yamamoto, N
Nakashima, H
Otaka, A
Fujii, N [1 ]
机构
[1] Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan
[2] Kagoshima Univ, Sch Dent, Dept Microbiol & Immunol, Kagoshima 8908544, Japan
[3] Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan
[4] Tohoku Univ, Grad Sch Med, Aoba Ku, Sendai, Miyagi 9808574, Japan
[5] Tokyo Med & Dent Univ, Sch Med, Bunkyo Ku, Tokyo 1138519, Japan
关键词
D O I
10.1016/S0960-894X(01)00323-7
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We previously reported a truncated polyphemusin peptide analogue, T140, which efficiently inhibits infection of target cells by T-cell line-tropic strains of HIV-1 (X4-HIV-1) through its specific binding to a chemokine receptor. CXCR4. We have found that T140 is not stable in feline serum due to the cleavage of the C-terminal Arg,(14) indispensable for anti-HIV activity. On the other hand, a C-terminally amidated analogue of T140, TZ14004, has been found to be completely stable in incubation in the serum for 2 days. The C-terminal amide is thought to be needed for stability in serum. However. TZ14004 does not have fairly strong anti-HIV activity, but has relatively strong cytotoxicity, probably due to an increase by + 1 charge from total + 7 charges of T140. In our previous study, the number of total + 6 charges seemed to be a suitable balance between activity and cytotoxicity. In this study, we have conducted a double-L-citrulline (Cit)-scanning study on TZ14004 based on the C-terminally amidated form in due consideration of the total net charges in the whole molecule to find novel effective CXCR4 inhibitors, TN14003 ([Cit(6)]-T140 with the C-terminal amide) and TC14012 ([Cit(6), D-Cit(8)]-T140 with the C-terminal amide), which possess high selectivity indexes (SIs) and complete stability in feline serum. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1897 / 1902
页数:6
相关论文
共 34 条
[1]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[2]   HIV blocked by chemokine antagonist [J].
ArenzanaSeisdedos, F ;
Virelizier, JL ;
Rousset, D ;
ClarkLewis, I ;
Loetscher, P ;
Moser, B ;
Baggiolini, M .
NATURE, 1996, 383 (6599) :400-400
[3]   The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates [J].
Choe, H ;
Farzan, M ;
Sun, Y ;
Sullivan, N ;
Rollins, B ;
Ponath, PD ;
Wu, LJ ;
Mackay, CR ;
LaRosa, G ;
Newman, W ;
Gerard, N ;
Gerard, C ;
Sodroski, J .
CELL, 1996, 85 (07) :1135-1148
[4]   AN INFECTIOUS MOLECULAR CLONE OF AN UNUSUAL MACROPHAGE-TROPIC AND HIGHLY CYTOPATHIC STRAIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
COLLMAN, R ;
BALLIET, JW ;
GREGORY, SA ;
FRIEDMAN, H ;
KOLSON, DL ;
NATHANSON, N ;
SRINIVASAN, A .
JOURNAL OF VIROLOGY, 1992, 66 (12) :7517-7521
[5]   INFECTION OF MONOCYTE-DERIVED MACROPHAGES WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) - MONOCYTE-TROPIC AND LYMPHOCYTE-TROPIC STRAINS OF HIV-1 SHOW DISTINCTIVE PATTERNS OF REPLICATION IN A PANEL OF CELL-TYPES [J].
COLLMAN, R ;
HASSAN, NF ;
WALKER, R ;
GODFREY, B ;
CUTILLI, J ;
HASTINGS, JC ;
FRIEDMAN, H ;
DOUGLAS, SD ;
NATHANSON, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (04) :1149-1163
[6]   Identification of a major co-receptor for primary isolates of HIV-1 [J].
Deng, HK ;
Liu, R ;
Ellmeier, W ;
Choe, S ;
Unutmaz, D ;
Burkhart, M ;
DiMarzio, P ;
Marmon, S ;
Sutton, RE ;
Hill, CM ;
Davis, CB ;
Peiper, SC ;
Schall, TJ ;
Littman, DR ;
Landau, NR .
NATURE, 1996, 381 (6584) :661-666
[7]   AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor [J].
Donzella, GA ;
Schols, D ;
Lin, SW ;
Esté, JA ;
Nagashima, KA ;
Maddon, PJ ;
Allaway, GP ;
Sakmar, TP ;
Henson, G ;
De Clercq, E ;
Moore, JP .
NATURE MEDICINE, 1998, 4 (01) :72-77
[8]   A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor [J].
Doranz, BJ ;
GrovitFerbas, K ;
Sharron, MP ;
Mao, SH ;
Goetz, MB ;
Daar, ES ;
Doms, RW ;
OBrien, WA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (08) :1395-1400
[9]   A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors [J].
Doranz, BJ ;
Rucker, J ;
Yi, YJ ;
Smyth, RJ ;
Samson, M ;
Peiper, SC ;
Parmentier, M ;
Collman, RG ;
Doms, RW .
CELL, 1996, 85 (07) :1149-1158
[10]   HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5 [J].
Dragic, T ;
Litwin, V ;
Allaway, GP ;
Martin, SR ;
Huang, YX ;
Nagashima, KA ;
Cayanan, C ;
Maddon, PJ ;
Koup, RA ;
Moore, JP ;
Paxton, WA .
NATURE, 1996, 381 (6584) :667-673